Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

EP 154 - Kristina Levan: Why Life-Saving Therapies Aren’t Reaching Patients—And How to Fix It

Mar 9, 20251 hr 53 minAudio

ATMPs, gene therapies, and cancer breakthroughs are here - but outdated regulations, high costs, and logistical bottlenecks are blocking access. What needs to change for hospitals to deliver these cures to patients who need them most? 💡 Here’s the harsh reality: Patients are waiting, but hospitals aren’t ready. The science exists, but regulations haven’t caught up. The treatments work, but they’re too expensive to scale. So what’s the solution? And who’s taking action? 📌 In this episode, Kristina Levan - ATMP innovation leader and biotech strategist - breaks down the challenges and opportunities shaping the future of advanced therapies. 🎧 Watch now to learn: 1️⃣ How gene therapy is curing blindness - and why it almost didn’t happen. 2️⃣ The biggest bottleneck preventing hospitals from offering life-saving treatments. 3️⃣ How AI and automation could unlock personalized medicine for everyone. 4️⃣ The real reason ATMPs are so expensive - and what must change. 5️⃣ Why healthcare leaders, policymakers, and investors must rethink how we manufacture cures. 👤 About Kristina Levan: Kristina Levan has spent years at the cutting edge of cancer research, clinical trials, and ATMP development. She’s helped shape Sweden’s national ATMP strategy, connecting industry, healthcare, and academia to push these breakthroughs forward. Now, she’s tackling the next big challenge - getting these treatments to patients faster. 💡 Quotes to Challenge Your Thinking: (00:12:05) "ATMPs don’t just treat symptoms - they have the power to cure diseases." (00:23:36) "Gene therapy is giving children a future - restoring sight and transforming their lives forever." (01:27:52) "Imagine a future where hospitals create customized gene therapies on-site for every patient." (01:43:13) "ATMPs could transform lives by treating the untreatable." (01:45:42) "If we can cure early, we don’t just save lives - we reshape them." Timestamps: (00:05:32) How ATMPs Will Reshape Global Healthcare (00:13:54) CAR-T Therapy: The Next Cancer Treatment Revolution (00:23:36) Gene Therapy Restores Sight - The Future of Medicine? (00:28:33) AI-Powered Therapies: Can Hospitals Manufacture Cures? (00:37:55) Why Cutting-Edge ATMPs Struggle to Reach Patients (00:53:36) Personalized Medicine & Real-Time Health Monitoring (01:09:02) From Research to Reality: Scaling ATMP Treatments (01:12:54) The True Cost of ATMPs - Can We Afford Innovation? (01:27:15) Cell Therapy Manufacturing: The Next Big Disruption (01:33:03) AI & Automation in Healthcare: What’s Next? 🔔 Help Us Grow If this episode gave you insight, inspiration, or a new perspective - here’s how you can help: 📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it has a huge ripple effect. Every engagement helps us bring in bigger guests, deeper insights, and more industry-changing conversations. Right now, we’re in the global top 10% - let’s push for the top 1% together. 🎧 Watch now and be part of the conversation shaping the future of medicine. 🚀 Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode